Combine and conquer: manganese synergizing anti-TGF-β/PD-L1 bispecific antibody YM101 to overcome immunotherapy resistance in non-inflamed cancers

Combine and conquer: manganese synergizing anti-TGF-β/PD-L1 bispecific antibody YM101 to overcome immunotherapy resistance in non-inflamed cancers

Abstract Background Our previous work showed that the anti-TGF-β/PD-L1 bispecific antibody YM101 effectively overcame anti-PD-L1 resistance in immune-excluded tumor models. However, in immune-desert models, the efficacy of YM101 was limited. Bivalent manganese (Mn2+) is identified as a natural stimu...

Full description

Bibliographic Details
Main Authors: Ming Yi, Mengke Niu, Jing Zhang, Shiyu Li, Shuangli Zhu, Yongxiang Yan, Ning Li, Pengfei Zhou, Qian Chu, Kongming Wu
Format: Article
Language:English
Published: BMC 2021-09-01
Series:Journal of Hematology & Oncology
Subjects:
The tumor microenvironment
Manganese
cGAS-STING
PD-L1
TGF-β
Bispecific antibody
Online Access:https://doi.org/10.1186/s13045-021-01155-6

Internet

https://doi.org/10.1186/s13045-021-01155-6

Similar Items